A new look at dry eye disease and its treatment.
This review examines the impact of moderate to severe dry eye disease on daily life and medical-resource utilization. The results suggest that current treatment paradigms can lead to unacceptable costs in both quality of life and progressive use of healthcare resources. Evidence linking this disease to T-cell-mediated inflammatory processes lays the foundation for understanding the clinical benefits of topical cyclosporine, an immunomodulatory and anti-inflammatory agent.
Nelson
J D
JD
HealthPartners Medical Group, Minneapolis, Regions Hospital, St. Paul, MN 55101, USA.
Helms
H
H
Fiscella
R
R
Southwell
Y
Y
Hirsch
J D
JD
D000328:Adult; D000368:Aged; D017281:Cost of Illness; D015352:Dry Eye Syndromes / Q000191:economics / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D014481:United States / Q000453:epidemiology